Drug
Brexanolone Zulresso
Brexanolone Zulresso: highest development phase Post-Market, developed by Sage Therapeutics. 1 trial record tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Sage Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| Brexanolone Injection [Zulresso] NCT05254405 | Post-Market | Post-Traumatic Stress Disorder |
Latest
No recent events.
Follow Brexanolone Zulresso on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.